A005690 Stock Overview
A biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pharmicell Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,440.00 |
| 52 Week High | ₩9,680.00 |
| 52 Week Low | ₩4,300.00 |
| Beta | 0 |
| 1 Month Change | 5.76% |
| 3 Month Change | 58.65% |
| 1 Year Change | 48.33% |
| 3 Year Change | -26.93% |
| 5 Year Change | 1.44% |
| Change since IPO | 249.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| A005690 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -5.6% | -2.7% | 0.3% |
| 1Y | 48.3% | 24.7% | -1.5% |
Return vs Industry: A005690 exceeded the KR Biotechs industry which returned 24.7% over the past year.
Return vs Market: A005690 exceeded the KR Market which returned -1.5% over the past year.
Price Volatility
| A005690 volatility | |
|---|---|
| A005690 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A005690 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A005690's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | n/a | Hyun-Soo Kim | www.pharmicell.com |
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty.
Pharmicell Co., Ltd. Fundamentals Summary
| A005690 fundamental statistics | |
|---|---|
| Market cap | ₩506.43b |
| Earnings (TTM) | -₩26.78b |
| Revenue (TTM) | ₩23.94b |
0.0x
P/S Ratio0.0x
P/E RatioIs A005690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A005690 income statement (TTM) | |
|---|---|
| Revenue | ₩23.94b |
| Cost of Revenue | ₩18.50b |
| Gross Profit | ₩5.45b |
| Other Expenses | ₩32.23b |
| Earnings | -₩26.78b |
Last Reported Earnings
Jun 30, 2014
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A005690 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/18 23:00 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2014/06/30 |
| Annual Earnings | 2013/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmicell Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |
| Nam Park | HSBC |
| Wan Ku | NH Investment & Securities Co., Ltd. |